Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States
Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Jun 5, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain changes in the cells of the blood vessels and immune system might affect patients who have experienced a serious condition called circulatory shock. Circulatory shock can lead to multiple organ problems and is life-threatening. While many patients survive, they often face new challenges, such as increased risk of infections and heart problems. The researchers believe that the aging of specific cells in the body could play a key role in these complications, and they aim to learn more about this connection.
To participate in this study, you need to be diagnosed with circulatory shock and have health insurance. The trial is open to all genders and is currently recruiting participants aged between 65 and 74. If you join, you will help researchers understand how these cell changes might lead to further health issues. This knowledge could eventually help develop better treatment plans to prevent these complications in the future.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Circulatory shock
- • patient with health care insurance
- Exclusion criteria:
- • Patients' refusal to participate in clinical research
- • Pregnant woman
- • Breastfeeding woman
- • A patient with a protective order
About University Hospital, Strasbourg, France
The University Hospital of Strasbourg, France, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the institution collaborates with a diverse range of healthcare professionals and research teams to explore cutting-edge therapies and treatment modalities. With state-of-the-art facilities and a multidisciplinary approach, the University Hospital of Strasbourg plays a pivotal role in translating scientific discoveries into effective clinical applications, contributing significantly to the advancement of medical knowledge and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Strasbourg, , France
Patients applied
Trial Officials
Ferhat MEZIANI
Principal Investigator
Hôpitaux Universitaires de Strasbourg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials